Smartox Biotechnology is specialized in studying properties of animal venoms and manufacturing synthetically most interesting venom peptides (such peptides are sometimes referred to as toxins). Smartox Biotechnology is a spin-off of the internationally renowned Grenoble Institute of Neuroscience (partly owned by the University Joseph Fourier, Grenoble, France). The company was initiated by the Dr Michel De Waard (profile) in 2009.
Dr De Waard’s field of research covers the strong link existing between ion channels and venom peptides, in particular the identification and the development of venom peptides as therapeutic molecules. This led the team to develop important know-how relating to venom studies such as venom fractionation, identification of pharmacologically active peptides, cystein-rich peptides characterization, manufacturing and optimization.
Smartox Biotechnology opens an access to animal venoms, an invaluable source of compounds in drug discovery and life-sciences research. Its outstanding technical expertise enables Smartox to offer a range of products & services including a catalog of synthetic toxins, a peptide synthesis service, screening libraries and hit-to-lead services.
The company has developed a screening library made of 40,000 constrained peptides isolated from animal venoms . These compounds are already known to modulate ion channels, GPCRs and integrins, and might have other targets to be discovered. VenomScreen library can be used in a large range of research area such as pain, cancer, autoimmune disorder, insecticides, anti-wrinkles.. Smartox Biotechnology is actively looking for pharmaceutic, agroscience and cosmetic partners interested in testing its compound library.
Specialist in the synthesis of simple as well as complex peptides, Smartox Biotechnology offers its services to synthesize your own peptides.
Smartox Biotechnology has not received any reviews.
Smartox Biotechnology has not received any endorsements.